PURPOSE: To analyze the dose/fractionation schedules currently used in ongoing clinical trials of partial breast irradiation (PBI) by comparing their biologically effective dose (BED) values to those of three standard whole breast protocols commonly used after segmental mastectomy in the treatment of breast cancer. METHODS AND MATERIALS: The BED equation derived from the linear-quadratic model for radiation-induced cell killing was used to calculate the BEDs for three commonly used whole breast radiotherapy regimens, in addition to a variety of external beam radiotherapy, as well as high-dose-rate and low-dose-rate brachytherapy, PBI protocols. RESULTS: The BED values of most PBI protocols resulted in tumor control BEDs roughly equivalent to a 50-Gy standard treatment, but consistently lower than the BEDs for regimens in which the tumor bed receives a total dose of either 60 Gy or 66 Gy. The BED values calculated for the acute radiation responses of erythema and desquamation were nearly all lower for the PBI schedules, and the late-response BEDs for most PBI regimens were in a similar range to the BEDs for the standard treatments. CONCLUSION: Biologically effective dose modeling raises the concern that inadequate doses might be delivered by PBI to ensure optimal in-field tumor control.
PURPOSE: To analyze the dose/fractionation schedules currently used in ongoing clinical trials of partial breast irradiation (PBI) by comparing their biologically effective dose (BED) values to those of three standard whole breast protocols commonly used after segmental mastectomy in the treatment of breast cancer. METHODS AND MATERIALS: The BED equation derived from the linear-quadratic model for radiation-induced cell killing was used to calculate the BEDs for three commonly used whole breast radiotherapy regimens, in addition to a variety of external beam radiotherapy, as well as high-dose-rate and low-dose-rate brachytherapy, PBI protocols. RESULTS: The BED values of most PBI protocols resulted in tumor control BEDs roughly equivalent to a 50-Gy standard treatment, but consistently lower than the BEDs for regimens in which the tumor bed receives a total dose of either 60 Gy or 66 Gy. The BED values calculated for the acute radiation responses of erythema and desquamation were nearly all lower for the PBI schedules, and the late-response BEDs for most PBI regimens were in a similar range to the BEDs for the standard treatments. CONCLUSION: Biologically effective dose modeling raises the concern that inadequate doses might be delivered by PBI to ensure optimal in-field tumor control.
Authors: Silvia C Formenti; Howard Hsu; Maria Fenton-Kerimian; Daniel Roses; Amber Guth; Gabor Jozsef; Judith D Goldberg; J Keith Dewyngaert Journal: Int J Radiat Oncol Biol Phys Date: 2012-04-09 Impact factor: 7.038
Authors: Jona A Hattangadi; Simon N Powell; Shannon M MacDonald; Thomas Mauceri; Marek Ancukiewicz; Phoebe Freer; Brian Lawenda; Mohamed A Alm El-Din; Michele A Gadd; Barbara L Smith; Alphonse G Taghian Journal: Int J Radiat Oncol Biol Phys Date: 2011-11-16 Impact factor: 7.038
Authors: Giovanni Paganelli; Concetta De Cicco; Mahila E Ferrari; Giuseppe Carbone; Gianmatteo Pagani; Maria Cristina Leonardi; Marta Cremonesi; Annamaria Ferrari; Monica Pacifici; Amalia Di Dia; Rita De Santis; Viviana Galimberti; Alberto Luini; Roberto Orecchia; Stefano Zurrida; Umberto Veronesi Journal: Eur J Nucl Med Mol Imaging Date: 2009-09-04 Impact factor: 9.236
Authors: David J Sher; Eve Wittenberg; Alphonse G Taghian; Jennifer R Bellon; Rinaa S Punglia Journal: Int J Radiat Oncol Biol Phys Date: 2007-10-29 Impact factor: 7.038
Authors: Dustin L Boothe; Shana Coplowitz; Eleni Greenwood; Christian L Barney; Paul J Christos; Bhupesh Parashar; Dattatreyudu Nori; K S Clifford Chao; A Gabriella Wernicke Journal: Int J Radiat Oncol Biol Phys Date: 2013-10-16 Impact factor: 7.038